Press release
Myelofibrosis Clinical Trial Pipeline Accelerates as 35+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight
Download DelveInsight's comprehensive Myelofibrosis Pipeline Report to explore emerging therapies, key Companies, and future treatment landscapes @ https://www.delveinsight.com/sample-request/myelofibrosis-pipeline-insight [https://www.delveinsight.com/sample-request/myelofibrosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Myelofibrosis Pipeline Report
* On January 23, 2026- Disc Medicine Inc. initiated a phase 1b/2a open-label study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of DISC-0974 as well as categorize the effects on anemia response in subjects with myelofibrosis or myelodysplastic syndrome and anemia.
* On January 20, 2026- AbbVie announced a Phase 2 open-label, multicenter study evaluating tolerability and efficacy of navitoclax alone or when added to ruxolitinib in participants with myelofibrosis.
* On January 16, 2026- iOnctura clinical trial is to learn how roginolisib works in comparison to standard treatment in adult patients with Myelofibrosis. The main questions it aims to answer is to evaluate the safety and tolerability of roginolisib when administered in combination with ruxolitinib.
* On January 09, 2026- Swedish Orphan Biovitrum conducted a study (study ID PAC203 North America; PAC303 ex-North America) is evaluating 200 mg BID of pacritinib compared to physician's choice (P/C) therapy in patients with MF and severe thrombocytopenia (platelet count
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Myelofibrosis Clinical Trial Pipeline Accelerates as 35+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight here
News-ID: 4373935 • Views: …
More Releases from ABNewswire
Historic Sultanate of Maguindanao Royal Friendship Event Bridges Culture, Charit …
Video: https://www.youtube.com/embed/AiWHU-MZGPo?si=5wspC0mqoE4fXXj-
Video Link: https://www.youtube.com/embed/AiWHU-MZGPo?si=5wspC0mqoE4fXXj-
The Sultanate of Maguindanao, in partnership with the non-profit organization We Care for Humanity (WCH), successfully convened the Sultanate of Maguindanao Royal Friendship Event on January 26, 2026, at the Em Manor Hotel and Convention Center. The gathering marked a significant milestone in fostering international unity, bringing together global dignitaries, royal families, and investors for a night dedicated to cultural exchange and economic partnership.
The evening commenced with…
Undervalued Stocks Under $2: SWVL, RDZN, SURG, CISS, DKI - Complete List Inside
Following Friday's market close, a select group of Nasdaq-listed stocks trading under $2 is gaining renewed attention across the investment community. As investors scan for undervalued small-cap stocks, Nasdaq penny stocks, and high-upside re-rating candidates, these companies stand out for having real operating businesses, identifiable growth narratives, and near-term catalysts that can drive volume expansion and valuation resets.
Unlike speculative shells, each of the names below operates in an active sector-mobility…
Should Pond Fountain Run All the Time? Expert Guidance for Healthier Ponds
Pond Haven, a trusted source for pond and lake equipment, is sharing expert guidance to help homeowners build healthier, more beautiful backyard ponds with improved circulation and oxygen levels while reducing stagnant-water problems that compromise water clarity and enjoyment.
Casper, WY - February 2, 2026 - Homeowners frequently ask whether pond fountains [https://pondhaven.com/blogs/news/should-a-pond-fountain-run-all-the-time] should run continuously, especially during hot weather, overnight, or when trying to keep water conditions stable. Pond Haven's…
2026 Chris Botti Tour Dates & Tickets: Discount Deals with Promo Code CITY10 - S …
Discover the 2026 Chris Botti tour dates and grab tickets at discounted prices with promo code CITY10 at CapitalCityTickets.com. Score the best seats, last-minute deals, and exclusive savings for his smooth jazz performances. Don't miss your chance to experience Chris Botti live in 2026-secure premium views, enjoy unforgettable shows, and save big on tickets across all tour stops nationwide.
Grammy-winning jazz trumpeter Chris Botti [https://www.capitalcitytickets.com/Chris-Botti-Tickets] is bringing his signature smooth, emotive…
More Releases for Myelofibrosis
Primary Myelofibrosis (PMF) Market Insights and Future Outlook
Introduction
Primary myelofibrosis (PMF) is a rare, chronic myeloproliferative neoplasm characterized by progressive bone marrow fibrosis, splenomegaly, anemia, and systemic symptoms such as fatigue, night sweats, and weight loss. Unlike secondary myelofibrosis, which arises from other blood cancers, PMF develops as a distinct disease entity, typically driven by mutations in JAK2, CALR, or MPL genes.
PMF has long been associated with poor prognosis and limited therapeutic options. Historically, treatment focused on symptom…
Myelofibrosis Pipeline Therapeutics Assessment Report 2024 (Updated)
DelveInsight's, "Myelofibrosis Pipeline Insight 2024" report provides comprehensive insights about 35+ companies and 40+ pipeline drugs in Myelofibrosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Myelofibrosis Research. Learn more about our innovative…
Secondary Myelofibrosis Therapeutics Market - Revolutionizing Treatment for Seco …
Newark, New Castle, USA: The "Secondary Myelofibrosis Therapeutics Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Secondary Myelofibrosis Therapeutics Market: https://www.growthplusreports.com/report/secondary-myelofibrosis-therapeutics-market/8885
This latest report researches the industry structure,…
Myelofibrosis Market - Transforming Challenges into Triumphs: Myelofibrosis Mark …
Newark, New Castle, USA: The "Myelofibrosis Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Myelofibrosis Market: https://www.growthplusreports.com/report/myelofibrosis-market/8802
This latest report researches the industry structure, sales, revenue, price and…
Secondary Myelofibrosis Therapeutics Market - Unleashing Resilience, Defying Mye …
Newark, New Castle, USA - new report, titled Secondary Myelofibrosis Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Secondary Myelofibrosis Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Secondary Myelofibrosis Therapeutics market. The report offers an overview of…
Chronic Idiopathic Myelofibrosis Market 2022 | Detailed Report
The Chronic Idiopathic Myelofibrosis report understands the current and future competitive scenario across types, countries, and applications.It provides accurate, up-to-date analysis of markets and companies.The report use reliable information and analysis to gain a deeper understanding of the current factors impacting the industry.
The Chronic Idiopathic Myelofibrosis report provides exact and accurate data that helps companies of all sizes to make timely decisions. Furthermore, the report provides robust solutions to customers,…
